Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

To compare the use of alternative nicotine products, smoking behavior and tobacco biomarker exposure in smokers unwilling to quit who were assigned randomly to normal nicotine content (NNC) cigarettes or very low nicotine content (VLNC) cigarettes.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Randomized, parallel-arm 8-week study with assignment to VLNC (VLNC 1, n = 53) or NNC (NNC, n = 27) with access to non-cigarette combusted and non-combusted tobacco/nicotine products or to VLNC with access to only non-combusted products (VLNC2, n = 56).

During the experimental period, the measures taken included: rate of alternative products used, amount of and abstinence from combusted tobacco used and tobacco exposure biomarkers.

How the Study Was Run

The researchers set it up as a randomized and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Cigarette Smoking, Nicotine, Tobacco Products and Tobacco Use Cessation Devices.

The authors tagged it with the keywords Alternative nicotine delivery systems, electronic cigarettes, exposure biomarkers, medicinal nicotine, nicotine regulation and product standards.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.